The relationship between serum ferritin levels and disease activity in systemic lupus erythematosus

2003 ◽  
Vol 32 (4) ◽  
pp. 225-228 ◽  
Author(s):  
E Beyan ◽  
C Beyan ◽  
A Demirezer ◽  
E Ertuğrul ◽  
A Uzuner
Lupus ◽  
2020 ◽  
Vol 29 (2) ◽  
pp. 182-190
Author(s):  
W Batista Cicarini ◽  
R C Figueiredo Duarte ◽  
K Silvestre Ferreira ◽  
C de Mello Gomes Loures ◽  
R Vargas Consoli ◽  
...  

We have explored the relationship between possible hemostatic changes and clinical manifestation of the systemic lupus erythematosus (SLE) as a function of greater or lesser disease activity according to Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) criteria. Endothelial injury and hypercoagulability were investigated in patients with SLE by measuring thrombomodulin (TM), D-dimer (DDi) and thrombin generation (TG) potential. A total of 90 participants were distributed into three groups: 1) women with SLE presenting with low disease activity (laSLE) (SLEDAI-2K ≤ 4), 2) women with SLE presenting with moderate to high disease activity (mhaSLE) (SLEDAI-2K > 4), and 3) a control group comprising healthy women. Levels of TM and DDi were higher both in the laSLE and mhaSLE groups compared to controls and in mhaSLE compared to the laSLE group. With respect to TG assay, lagtime and endogen thrombin potential, low concentrations of tissue factor provided the best results for discrimination among groups. Analysis of these data allow us to conclude that TM, DDi and TG are potentially useful markers for discriminating patients with very active from those with lower active disease. Higher SLE activity may cause endothelial injury, resulting in higher TG and consequently a hypercoagulability state underlying the picture of thrombosis common in this inflammatory disease.


2020 ◽  
Author(s):  
Lambros Athanassiou ◽  
Ifigenia Kostoglou ◽  
Pavlos Tsakiridis ◽  
Aikaterini Tzanavari ◽  
Eirini Devetzi ◽  
...  

2018 ◽  
Vol 33 (4) ◽  
pp. 823-828 ◽  
Author(s):  
Chang-Nam Son ◽  
Tae-Han Lee ◽  
Ji-Hye Bang ◽  
Hye-Jin Jeong ◽  
Jin-Nyeong Chae ◽  
...  

Lupus ◽  
2019 ◽  
Vol 28 (8) ◽  
pp. 986-994 ◽  
Author(s):  
A Nishino ◽  
Y Katsumata ◽  
H Kawasumi ◽  
S Hirahara ◽  
Y Kawaguchi ◽  
...  

ObjectiveWe aimed to study the usefulness of serum soluble CD163 (sCD163) as a biomarker for macrophage activation syndrome (MAS) associated with systemic lupus erythematosus (SLE).MethodsSerum sCD163 levels were retrospectively measured by enzyme-linked immunosorbent assay for SLE patients associated with MAS (SLE-MAS), lupus nephritis (LN), or autoimmune hemolytic anemia (AIHA) and/or immune thrombocytopenia (ITP) and healthy controls (HCs). Posttreatment samples were also evaluated in the available SLE-MAS patients. The associations between serum sCD163 levels and clinical information were statistically analyzed.ResultsThe serum sCD163 levels in SLE-MAS, LN and SLE-AIHA/ITP groups were significantly higher than those in HCs ( n = 17, 29, 13, and 68, respectively; p < 0.01 for all comparisons). In addition, the serum sCD163 levels in the SLE-MAS group were even higher than those in the LN and SLE-AIHA/ITP groups ( p < 0.01 for both comparisons). Serum sCD163 levels were correlated with the SLE Disease Activity Index 2000 scores ( r = 0.53), whereas they were not correlated with the serum ferritin levels. With the determined cut-off value, the sensitivity and specificity of serum sCD163 for the diagnosis of SLE-MAS were 59% and 86%, respectively. Retesting showed that the serum sCD163 levels decreased significantly following treatment in parallel with disease amelioration in the SLE-MAS group ( p < 0.01).ConclusionsThe present study suggests the usefulness of serum sCD163 as a diagnostic and disease-activity biomarker for SLE-associated MAS. Serum sCD163 might also have a different role as a biomarker for SLE-associated MAS than serum ferritin does.


2009 ◽  
Vol 36 (5) ◽  
pp. 947-952 ◽  
Author(s):  
SIMONE APPENZELLER ◽  
ANN E. CLARKE ◽  
PANTELIS PANOPALIS ◽  
LAWRENCE JOSEPH ◽  
YVAN ST. PIERRE ◽  
...  

Objective.To evaluate the relationship between renal activity and quality of life (QOL) in patients with systemic lupus erythematosus (SLE).Methods.Three hundred eighty-six patients completed annual Medical Outcomes Study Short Form-36 questionnaires and physicians completed the SLE Disease Activity Index and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. Concurrent association between renal activity and QOL was evaluated through regression models that adjusted for demographics and nonrenal disease activity and nonrenal damage. To characterize the longitudinal relationship between change in renal activity and change in QOL, all renal activity and QOL data over the entire study were used to estimate a linear trend within each individual patient through hierarchical modeling.Results.In the regression model that assessed the association between renal activity and QOL, on average, each additional renal activity item fulfilled was associated with a 2.04-unit (95% CI 0.88, 3.24) decrease in the physical function subscale, a 5.28-unit (95% CI 2.76, 7.76) decrease in the role-physical subscale, a 2.24-unit (95% CI 0.72, 3.80) decrease in the social function subscale, and a 1.16-unit (95% CI 0.60, 1.72) decrease in the physical component summary score. In the hierarchical model, no association was observed between changes in renal activity and QOL.Conclusion.Patients with SLE and active renal disease concurrently experience a slightly poorer QOL than those without renal disease, especially in the physical domains. Because the confidence intervals were wide, we could not accurately estimate whether a longitudinal change in renal activity was associated with a change in QOL.


2013 ◽  
Vol 63 (1-2) ◽  
pp. 77-82 ◽  
Author(s):  
Thaís Tobaruela Ortiz ◽  
Maria Teresa Terreri ◽  
Michelle Caetano ◽  
Fabíola Suano Souza ◽  
Vânia D'Almeida ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document